Clinical Trials
47 trialsNCT04238819 2026-03-02
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
Phase 1/2 Completed
NCT02942264 2026-02-23
Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT03687957 2025-11-25
rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide
Washington University School of Medicine
Phase 1/2 Active not recruiting
NCT02655601 2025-06-08
BMX-HGG
BioMimetix JV, LLC
Phase 1/2 Completed
NCT03554473 2025-05-09
M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT02715609 2025-04-10
Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Washington University School of Medicine
Phase 1/2 Completed
NCT03914742 2025-01-14
BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT04421378 2024-12-16
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
Karyopharm Therapeutics Inc
Phase 1/2 Terminated
NCT00555399 2024-08-22
Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT01505608 2024-08-06
Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma
Milton S. Hershey Medical Center
Phase 1/2 Terminated
NCT02052648 2024-03-27
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Lumos Pharma
Phase 1/2 Completed
NCT02315534 2023-11-15
A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma
Sumitomo Pharma America, Inc.
Phase 1/2 Completed
NCT03190967 2023-10-11
T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT02661282 2023-06-18
Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00667953 2023-03-30
Study of Temzolomide and Gleevec in Advanced Melanoma
Abramson Cancer Center at Penn Medicine
Phase 1/2 Terminated
NCT03119064 2022-12-13
329
Brown University
Phase 1/2 Terminated
NCT00731731 2022-08-04
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00669669 2022-05-18
O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT01110876 2021-08-25
Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT01120639 2021-08-06
Tx-Treatment
Stanford University
Phase 1/2 Completed
NCT01465659 2021-08-05
Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery
Northwestern University
Phase 1/2 Completed
NCT02116777 2021-03-26
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00050986 2020-09-22
Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01590082 2020-09-02
Doxycycline, Temozolomide and Ipilimumab in Melanoma
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT00402116 2020-08-06
Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients
Eli Lilly and Company
Phase 1/2 Completed
NCT00576680 2020-07-09
RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT01790503 2020-06-30
A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma
Daiichi Sankyo
Phase 1/2 Completed
NCT00553150 2020-02-13
Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Alliance for Clinical Trials in Oncology
Phase 1/2 Completed
NCT00869401 2020-02-13
Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Alliance for Clinical Trials in Oncology
Phase 1/2 Completed
NCT01196416 2019-11-18
Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01514201 2019-08-13
Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01601535 2019-07-31
Study of MLN8237 in Combination With Irinotecan and Temozolomide
New Approaches to Neuroblastoma Therapy Consortium
Phase 1/2 Completed
NCT00486603 2019-07-10
Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT00301067 2019-06-04
Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma
Northwestern University
Phase 1/2 Completed
NCT00441142 2019-03-05
Zactima
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT01044966 2019-02-12
A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma
Medical University of South Carolina
Phase 1/2 Terminated
NCT01977677 2018-10-23
Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma
Stanford University
Phase 1/2 Completed
NCT00305864 2018-03-05
Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00068250 2018-02-07
Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Radiation Therapy Oncology Group
Phase 1/2 Completed
NCT00715793 2017-10-03
UPCI-07-008
University of Pittsburgh
Phase 1/2 Completed
NCT00925132 2017-07-02
Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat
University of Iowa
Phase 1/2 Terminated
NCT01026493 2017-07-02
Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma
Radiation Therapy Oncology Group
Phase 1/2 Completed
NCT00362817 2017-06-01
Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases
Ohio State University Comprehensive Cancer Center
Phase 1/2 Completed
NCT00085254 2016-02-25
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00026494 2016-01-18
Temozolomide and Vinorelbine in Treating Patients With Recurrent Brain Metastases
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00939991 2013-06-24
Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas
Duke University
Phase 1/2 Completed
NCT00512798 2012-10-02
Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma
Vanderbilt-Ingram Cancer Center
Phase 1/2 Terminated